Enliven Therapeutics, Inc. (ELVN)
44.78
-0.40
(-0.87%)
USD |
NASDAQ |
Sep 25, 16:00
44.78
0.00 (0.00%)
After-Hours: 17:50
Enliven Therapeutics Research and Development Expense (Annual) : 85.59M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 85.59M |
| December 31, 2024 | 80.46M |
| December 31, 2023 | 64.28M |
| December 31, 2022 | 18.94M |
| December 31, 2021 | 20.36M |
| Date | Value |
|---|---|
| December 31, 2020 | 32.15M |
| December 31, 2019 | 19.01M |
| December 31, 2018 | 8.239M |
| December 31, 2017 | 7.918M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Definium Therapeutics, Inc. | 117.66M |
| Cocrystal Pharma, Inc. | 5.055M |
| CNBX Pharmaceuticals, Inc. | 0.00 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 282.90M |